p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.
Oppel F, Shao S, Gendreizig S, Zimmerman MW, Schürmann M, Flavian VF, Goon P, Chi SN, Aster JC, Sudhoff H, et al. Mol Cancer Ther. 2022 Nov 3; 21(11):1689-1700.